Press Releases

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 38th Annual J.P.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to participate in the following investor

Third quarter revenue of $21.2 million, an increase of 32% compared to prior year period Gross margin of 73%, an increase of 150 basis points from the prior year period Positive net income of $0.7 million compared to a net loss of ($3.5) million in prior year period OXFORD, United Kingdom and

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2019 financial results before the open of the market on

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial

Second quarter revenue of $19.6 million, an increase of 18% compared to prior year period Gross margin of 72.4%, reflecting our shift towards a pure-play kit business Positive net income of $0.6 million compared to a net loss of $6.5 million in prior year period OXFORD, United Kingdom and

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2019 financial results before the open of the market on